Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer

Academic Article

Abstract

  • Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m2 intravenously. The toxicity was moderate, with thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies to warrant further evaluation. © 1993 Kluwer Academic Publishers.
  • Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 26692204
  • Author List

  • Moore M; Maroun J; Robert F; Natale R; Neidhart J; Dallaire B; Sisk R; Gyves J
  • Start Page

  • 61
  • End Page

  • 65
  • Volume

  • 11
  • Issue

  • 1